Literature DB >> 2449410

Monoclonal antibody definition of multiple polymorphic epitopes on human leukocyte antigen-DRw52.

S V Fuggle1, C Carter, F Watts, J Kirkley, P J Morris.   

Abstract

Monoclonal antibodies have revealed complexity within the human leukocyte antigen class II antigens. We have studied epitopes present on a DR3 homozygous B-lymphoblastoid cell line using five polymorphic monoclonal antibodies produced and characterized in our laboratory. Serological analysis on a panel of B-cell lines revealed that the antibodies have different, but related, specificities (NDS9-anti-DR3, NDS10-anti-DR5, less than 3, less than w6, NDS11-anti-DR3, 5, w6, NDS12-anti-DR3, 5, w6, w8, NDS13-anti-DR3, 5, w6, w8+). Competitive radioimmunoassays and two-dimensional gel analyses demonstrated that whereas the epitopes recognized by the broadly reactive antibodies NDS10, 11, 12, and 13 reside on the same molecule, the epitope detected by NDS9 is present on a molecule with different electrophoretic mobility. Thus, using polymorphic monoclonal antibodies, we have defined multiple epitopes associated with DR3, which have different distributions at the population level.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2449410     DOI: 10.1016/0198-8859(87)90107-8

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  3 in total

1.  HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ, and HLA-DP.

Authors:  Rene J Duquesnoy; Medhat Askar
Journal:  Hum Immunol       Date:  2006-10-30       Impact factor: 2.850

2.  Analysis of restriction fragment length polymorphism for the HLA-DR gene in Japanese patients with sarcoidosis.

Authors:  H Kunikane; S Abe; E Yamaguchi; J M Aparicio; A Wakisaka; T Yoshiki; Y Kawakami
Journal:  Thorax       Date:  1994-06       Impact factor: 9.139

3.  A mutant human histocompatibility leukocyte antigen DR molecule associated with invariant chain peptides.

Authors:  E Mellins; P Cameron; M Amaya; S Goodman; D Pious; L Smith; B Arp
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.